Trial · NCT06029673
Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss
NCT06029673, Phase 2, Completed, Stanford University; results first posted 2025-10-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss. Trials, record NCT06029673. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06029673
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss
- NCT number
- NCT06029673
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 69 participants, actual
- Lead sponsor
- Stanford University
- Conditions
- Lactation Suppressed
- Interventions
- Cabergoline 1 MG, Placebo
- First posted
- 2023-09-08
- Last updated
- 2025-10-03
- Results first posted
- 2025-10-03
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Reporting Breast Pain | Day 4 after procedure | Participants will assess their breast symptoms using the validated Bristol Breast Inventory survey to assess 4 domains of breast symptoms: tenderness, engorgement, leaking milk, pain relief. Participants who indicated symptoms in any of these areas met the criteria for this outcome. |
| Secondary | Number of Participants Experiencing Side-effects | Cumulative over 2 weeks | Participants selected from previously documented side-effects from the dopaminergic class or entered as free-text. Participants may have reported more than one side-effect. The experience of dopaminergetic medication side effects may or may not be considered to be adverse events. |
| Secondary | Number of Participants Reporting Significant Bother From Breast Pain | Day 4 after procedure | Assessed using a Facial Pain Score; scale range 0-6 (higher scores indicate greater pain), with significant bother \>=4 |
| Secondary | Number of Participants Reporting Significant Bother From Side-effects | Cumulative over 2 weeks | Assessed using a Facial Pain Score; scale range 0-6 (higher scores indicate greater pain), with significant bother \>=4 |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Reporting Breast Pain | Day 4 after procedure | ITT analysis - participants that did not provide any additional surveys beyond date of enrollment were excluded | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Experiencing Side-effects | Cumulative over 2 weeks | ITT analysis - participants that did not provide any additional surveys beyond date of enrollment were excluded | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Reporting Significant Bother From Breast Pain | Day 4 after procedure | ITT analysis - participants that did not provide any additional surveys beyond date of enrollment were excluded | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Reporting Significant Bother From Side-effects | Cumulative over 2 weeks | ITT analysis - participants that did not provide any additional surveys beyond date of enrollment were excluded | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Reporting Breast Pain | Cabergoline | 16 | Participants | ||
| Number of Participants Reporting Breast Pain | Placebo | 30 | Participants | ||
| Number of Participants Experiencing Side-effects | Cabergoline | 26 | Participants | ||
| Number of Participants Experiencing Side-effects | Placebo | 31 | Participants | ||
| Number of Participants Reporting Significant Bother From Breast Pain | Cabergoline | 1 | Participants | ||
| Number of Participants Reporting Significant Bother From Breast Pain | Placebo | 7 | Participants | ||
| Number of Participants Reporting Significant Bother From Side-effects | Cabergoline | 1 | Participants | ||
| Number of Participants Reporting Significant Bother From Side-effects | Placebo | 1 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cabergoline | 34 | |
| Overall Study | STARTED | Placebo | 35 | |
| Overall Study | COMPLETED | Cabergoline | 32 | |
| Overall Study | COMPLETED | Placebo | 34 | |
| Overall Study | NOT COMPLETED | Cabergoline | 2 | |
| Overall Study | NOT COMPLETED | Placebo | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cabergoline | 0 | 34 |
| Total, all-cause mortality | Placebo | 0 | 35 |
| Total, other adverse events | Cabergoline | 0 | 34 |
| Total, other adverse events | Placebo | 0 | 35 |
| Total, serious adverse events | Cabergoline | 0 | 34 |
| Total, serious adverse events | Placebo | 0 | 35 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41538804 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons6
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Cabergoline vs Placebo: Number of Participants Reporting Breast Pain | Trial comparisons |
| Cabergoline vs Placebo: Number of Participants Reporting Significant Bother From Side-effects | Trial comparisons |
| Cabergoline vs Placebo: Number of Participants Experiencing Side-effects | Trial comparisons |
| Cabergoline vs Placebo: Number of Participants Reporting Significant Bother From Breast Pain | Trial comparisons |
| Cabergoline vs Placebo: deaths from any cause | Trial comparisons |
| Cabergoline vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06029673
GET https://conductscience.org/api/trials/v1/NCT06029673/registered